These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36104273)

  • 1. A Case of Osimertinib-Induced Eosinophilic Pneumonia.
    Patel KG; Corbett RL; Karanjawala ZE; Kelly KA; Stollenwerk N; Riess JW
    Clin Lung Cancer; 2022 Nov; 23(7):639-642. PubMed ID: 36104273
    [No Abstract]   [Full Text] [Related]  

  • 2. Fatal interstitial lung disease associated with AZD9291.
    Deng SM; Huang JA; Chen YB
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1227-S1229. PubMed ID: 30539877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review.
    Itano J; Higo H; Ohashi K; Makimoto G; Nishii K; Hotta K; Miyahara N; Maeda Y; Kiura K
    Intern Med; 2020 Mar; 59(6):823-828. PubMed ID: 31787696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Welcome to the Real World: Understanding the Many Faces of Osimertinib-Related Pneumonitis.
    Possick JD
    Chest; 2022 Nov; 162(5):965-967. PubMed ID: 36344125
    [No Abstract]   [Full Text] [Related]  

  • 5. Osimertinib-induced urticarial vasculitis in a patient with lung cancer: A rare cutaneous toxicity.
    Weng PC; Huang YL; Cheng CY
    Eur J Cancer; 2024 Jan; 196():113432. PubMed ID: 37995596
    [No Abstract]   [Full Text] [Related]  

  • 6. Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer.
    Häntschel M; Niebling J; Häring A; Häring MF; Groß T; Horger M; Riessen R; Haap M; Lewis RA; Böckeler M; Hetzel J
    Thorac Cancer; 2020 Jul; 11(7):2044-2047. PubMed ID: 32374485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation.
    Kawamura T; Kenmotsu H; Kobayashi H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Takahashi T
    Invest New Drugs; 2020 Feb; 38(1):194-201. PubMed ID: 31183631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication.
    Lee H; Lee HY; Sun JM; Lee SH; Kim Y; Park SE; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2018 Aug; 13(8):1106-1112. PubMed ID: 29775809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature.
    Sato I; Mizuno H; Kataoka N; Kunimatsu Y; Tachibana Y; Sugimoto T; Tani N; Ogura Y; Hirose K; Takeda T
    Medicina (Kaunas); 2020 Aug; 56(8):. PubMed ID: 32796633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.
    Lin G; Liu Y; Li H; Chen S; Guo Y
    Clin Lung Cancer; 2021 Mar; 22(2):e157-e159. PubMed ID: 33158763
    [No Abstract]   [Full Text] [Related]  

  • 11. Osimertinib-induced severe interstitial lung disease: A case report.
    Fan M; Mo T; Shen L; Yang L
    Thorac Cancer; 2019 Jul; 10(7):1657-1660. PubMed ID: 31241220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia.
    Tachi H; Shiozawa T; Sakai C; Kasuga M; Nakazawa K; Morishima Y; Satoh H; Hizawa N; Sakashita S; Sekine I
    J Thorac Oncol; 2017 Aug; 12(8):e118-e120. PubMed ID: 28748819
    [No Abstract]   [Full Text] [Related]  

  • 14. Osimertinib-related venous thromboembolism in non small lung cancer.
    Petrelli F; Cabiddu M; Borgonovo K; Parati MC; Ghilardi M; Perego G; Luciani A
    Thromb Res; 2022 Feb; 210():63-66. PubMed ID: 35007938
    [No Abstract]   [Full Text] [Related]  

  • 15. Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.
    Sala L; Mancin M; Pastore A; Seminati D; Cortinovis D; Bidoli P; Alberti A
    Lung Cancer; 2020 Apr; 142():120-122. PubMed ID: 32145595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
    Provencio M; Terrasa J; Garrido P; Campelo RG; Aparisi F; Diz P; Aguiar D; García-Giron C; Hidalgo J; Aguado C; González JG; Esteban E; Gómez-Aldavarí L; Moran T; Juan O; Chara LE; Marti JL; Castro RL; Ortega AL; Moreno EM; Coves J; Sánchez Peña AM; Bosch-Barrera J; Gastaldo AS; Núñez NF; Del Barco E; Cobo M; Isla D; Majem M; Navarro F; Calvo V
    BMC Cancer; 2021 Mar; 21(1):230. PubMed ID: 33676426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease.
    McLean LS; Faisal W; Parakh S; Kao SC; Lewis CR; Chin MT; Voskoboynik M; Itchins MJ; Jennens RR; Broad AR; Morris TA; Solomon BJ
    JCO Precis Oncol; 2021 Nov; 5():561-568. PubMed ID: 34994604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful osimertinib retreatment after extremely early onset severe pneumonitis in first-line treatment of lung adenocarcinoma.
    Ahn JH
    Thorac Cancer; 2020 Sep; 11(9):2713-2716. PubMed ID: 32666714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pulmonary manifestations induced by osimertinib].
    Le Guen Y; Lederlin M; Triquet L; Lesouhaitier M; Le Tulzo Y; Ricordel C
    Rev Mal Respir; 2022 Jan; 39(1):62-66. PubMed ID: 34969538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ASTRIS: a global real-world study of osimertinib in >3000 patients with
    Marinis F; Wu YL; de Castro G; Chang GC; Chen YM; Cho BC; Freitas HC; Jiang L; Kim SW; Martin C; Metro G; Provencio M; Vansteenkiste J; Vicente D; Zhou Q; Miranda MF; Bakker NA; Rigas JR; Cheema PK
    Future Oncol; 2019 Sep; 15(26):3003-3014. PubMed ID: 31339357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.